Hoth Therapeutics Inc Market Cap ($15.67 Million)
Market Cap & Net Worth: Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics Inc market cap. Hoth Therapeutics Inc (NASDAQ:HOTH) has a market capitalization of $15.67 Million ($15.67 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25696 globally and #5422 in its home market, demonstrating a -36.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hoth Therapeutics Inc's stock price $0.82 by its total outstanding shares 19127643 (19.13 Million). Also see HOTH cash flow metrics for how efficiently the company converts equity into cash flow.
Hoth Therapeutics Inc Market Cap History (2019–2026)
Hoth Therapeutics Inc market cap history from 2019 to 2026. Data shows change from $2.96 Billion to $15.67 Million (-52.73% CAGR). Check Hoth Therapeutics Inc share price for real-time trading data and today's change.
Index Memberships
Hoth Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #716 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2353 of 3165 |
Weight: Hoth Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hoth Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hoth Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hoth Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HOTH by Market Capitalization
Companies near Hoth Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see Hoth Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Hoth Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Hoth Therapeutics Inc (2019–2026)
Market capitalization of Hoth Therapeutics Inc from 2019 to today. Between 2019 and today, Hoth Therapeutics Inc's market cap moved from $2.96 Billion to $ 15.67 Million, with a yearly change of -52.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.67 Million | -17.24% |
| 2025 | $18.94 Million | +32.34% |
| 2024 | $14.31 Million | -48.05% |
| 2023 | $27.54 Million | -81.54% |
| 2022 | $149.20 Million | -52.73% |
| 2021 | $315.61 Million | -72.15% |
| 2020 | $1.13 Billion | -61.71% |
| 2019 | $2.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Hoth Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.67 Million USD |
| MoneyControl | $15.67 Million USD |
| MarketWatch | $15.67 Million USD |
| marketcap.company | $15.67 Million USD |
| Reuters | $15.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more